Biometric Research Program (BRP)

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Predictive Biomarkers in Phase II/III Clinical Trials

Biomarker Targeted Randomized Design

Biomarker Stratified Randomized Design

Binary Endpoint

Time-to-Event Endpoint

Optimal Two-Stage Designs For Phase II Clinical Trials

Integrated Phase II/III Study

Sample Size Planning for Developing Classifiers Using High Dimensional Data

Design, Monitoring and Analysis of Bayesian Basket Discovery Trials

Bayesian Phase II Single Arm Clinical Trials (Binary Outcomes)

Bayesian Phase II Single Arm Clinical Trials (Time to Event Outcomes)

Online Sample Size Calculation

Last Updated:

Predictive Biomarkers in Phase II/III Clinical Trials

Biomarker Targeted Randomized Design

Targeted design randomizes only marker positive patients to treatment or control arm. Untargeted design does not measure marker and randomizes all who otherwise are eligible.